| Title |
Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review
|
|---|---|
| Published in |
Targeted Oncology, March 2018
|
| DOI | 10.1007/s11523-018-0558-1 |
| Pubmed ID | |
| Authors |
Cédric Rossi, Marie-Lorraine Chrétien, René-Olivier Casasnovas |
| Abstract |
Antibody-drug conjugates (ADCs) are an emerging class of therapeutic agents that bring new opportunities for the treatment of hematological malignancies by meeting unmet medical needs. These drugs consist of a cytotoxic agent connected by a linker to a human, humanized, or chimeric antibody targeting a surface antigen specifically expressed by tumor cells. These ADCs are being developed to specifically deliver the cytotoxic agent into tumor cells. The cytotoxic payload is released from the ADC after internalization and cleavage of the linker, ultimately triggering the death of the cancer cell. Second- and even third-generation ADCs are currently being developed and have more stable linkers and more potent payloads, which should improve ADC efficacy even further. In this review, we analyze the results for the main ADCs currently developed and discuss the advantages and drawbacks of this therapeutic option. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 23% |
| Researcher | 6 | 15% |
| Student > Master | 5 | 13% |
| Other | 3 | 8% |
| Student > Doctoral Student | 1 | 3% |
| Other | 4 | 10% |
| Unknown | 12 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 6 | 15% |
| Medicine and Dentistry | 6 | 15% |
| Nursing and Health Professions | 3 | 8% |
| Agricultural and Biological Sciences | 3 | 8% |
| Chemistry | 2 | 5% |
| Other | 7 | 18% |
| Unknown | 13 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#1,833,495
of 25,255,356 outputs
Outputs from Targeted Oncology
#10
of 610 outputs
Outputs of similar age
#38,943
of 338,360 outputs
Outputs of similar age from Targeted Oncology
#1
of 17 outputs
Altmetric has tracked 25,255,356 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 610 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,360 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.